{"url_path":"/sec/ions/8-k/2026-06-24/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/874015/0001140361-26-026232-index.html","accession_number":"0001140361-26-026232","cik":"0000874015","ticker":"IONS","issuer_name":"IONIS PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/874015/0001140361-26-026232-index.html","primary_entity_key":"0000874015","primary_entity_name":"IONIS PHARMACEUTICALS INC"},"word_count":151,"has_tables":true,"body_markdown":"Item 7.01          Regulation FD Disclosure.\n\nOn June 24, 2026, Ionis Pharmaceuticals, Inc. (“Ionis”)\nissued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has approved TRYNGOLZA® (olezarsen) as an adjunct to\ndiet to reduce triglycerides (“TG”) and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (“sHTG”: TG greater than or equal to 500 mg/dL). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information in this Item 7.01 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as\namended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in\nany filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing."}